Literature DB >> 28770481

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Kedar R Mahajan1, Daniel Ontaneda2.   

Abstract

Magnetic resonance imaging has been crucial in the development of anti-inflammatory disease-modifying treatments. The current landscape of multiple sclerosis clinical trials is currently expanding to include testing not only of anti-inflammatory agents, but also neuroprotective, remyelinating, neuromodulating, and restorative therapies. This is especially true of therapies targeting progressive forms of the disease where neurodegeneration is a prominent feature. Imaging techniques of the brain and spinal cord have rapidly evolved in the last decade to permit in vivo characterization of tissue microstructural changes, connectivity, metabolic changes, neuronal loss, glial activity, and demyelination. Advanced magnetic resonance imaging techniques hold significant promise for accelerating the development of different treatment modalities targeting a variety of pathways in MS.

Entities:  

Keywords:  Advanced imaging; Clinical trials; MRI; Magnetic resonance imaging; Multiple sclerosis

Mesh:

Year:  2017        PMID: 28770481      PMCID: PMC5722766          DOI: 10.1007/s13311-017-0561-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  309 in total

1.  High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report.

Authors:  Cornelia Laule; Andrew Yung; Vlady Pavolva; Barry Bohnet; Piotr Kozlowski; Stanley A Hashimoto; Stephen Yip; David Kb Li; Gr Wayne Moore
Journal:  Mult Scler       Date:  2016-01-27       Impact factor: 6.312

2.  Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging.

Authors:  David Pitt; Aaron Boster; Wei Pei; Eric Wohleb; Adam Jasne; Cherian R Zachariah; Kottil Rammohan; Michael V Knopp; Petra Schmalbrock
Journal:  Arch Neurol       Date:  2010-07

3.  Topography of brain sodium accumulation in progressive multiple sclerosis.

Authors:  Adil Maarouf; Bertrand Audoin; Simon Konstandin; Audrey Rico; Elisabeth Soulier; Françoise Reuter; Arnaud Le Troter; Sylviane Confort-Gouny; Patrick J Cozzone; Maxime Guye; Lothar R Schad; Jean Pelletier; Jean-Philippe Ranjeva; Wafaa Zaaraoui
Journal:  MAGMA       Date:  2013-08-03       Impact factor: 2.310

4.  Inversion recovery ultrashort echo time magnetic resonance imaging: A method for simultaneous direct detection of myelin and high signal demonstration of iron deposition in the brain - A feasibility study.

Authors:  Vipul R Sheth; Shujuan Fan; Qun He; Yajun Ma; Jacopo Annese; Robert Switzer; Jody Corey-Bloom; Graeme M Bydder; Jiang Du
Journal:  Magn Reson Imaging       Date:  2016-12-28       Impact factor: 2.546

5.  18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.

Authors:  Datta E Ponde; Carmen S Dence; Nobuyuki Oyama; Joonyoung Kim; Yuan-Chuan Tai; Richard Laforest; Barry A Siegel; Michael J Welch
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

6.  Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.

Authors:  J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

7.  Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.

Authors:  Paul E Sijens; Jop P Mostert; Roy Irwan; Jan Hendrik Potze; Matthijs Oudkerk; Jacques De Keyser
Journal:  Psychiatry Res       Date:  2008-12-30       Impact factor: 3.222

8.  Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.

Authors:  Paolo Giannetti; Marios Politis; Paul Su; Federico E Turkheimer; Omar Malik; Shiva Keihaninejad; Kit Wu; Adam Waldman; Richard Reynolds; Richard Nicholas; Paola Piccini
Journal:  Brain       Date:  2014-11-21       Impact factor: 13.501

Review 9.  Sodium channel blockers for neuroprotection in multiple sclerosis.

Authors:  Chunsong Yang; Zilong Hao; Lingli Zhang; Linan Zeng; Jin Wen
Journal:  Cochrane Database Syst Rev       Date:  2015-10-21

10.  Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

Authors:  Rhian Raftopoulos; Simon J Hickman; Ahmed Toosy; Basil Sharrack; Shahrukh Mallik; David Paling; Daniel R Altmann; Marios C Yiannakas; Prasad Malladi; Rose Sheridan; Ptolemaios G Sarrigiannis; Nigel Hoggard; Martin Koltzenburg; Claudia A M Gandini Wheeler-Kingshott; Klaus Schmierer; Gavin Giovannoni; David H Miller; Raju Kapoor
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

View more
  11 in total

Review 1.  The vast potential and bright future of neuroimaging.

Authors:  Max Wintermark; Rivka Colen; Christopher T Whitlow; Greg Zaharchuk
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

2.  Vitamin D and MRI measures in progressive multiple sclerosis.

Authors:  Justin R Abbatemarco; Robert J Fox; Hong Li; Daniel Ontaneda
Journal:  Mult Scler Relat Disord       Date:  2019-08-13       Impact factor: 4.339

3.  Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.

Authors:  Emily M Bateman; Wolfgang E Schleicher; Elana J Smith; David R Sweet; Andrew D Gaudet
Journal:  Neurology       Date:  2018-02-20       Impact factor: 9.910

4.  Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Authors:  Devon S Conway; Le H Hua; Jeffrey A Cohen
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 5.  Remyelinating Pharmacotherapies in Multiple Sclerosis.

Authors:  Riley M Bove; Ari J Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 6.  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Authors:  Laura E Baldassari; Robert J Fox
Journal:  Drugs       Date:  2018-10       Impact factor: 11.431

7.  Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS.

Authors:  Abdulaziz Alshehri; Oun Al-Iedani; Jameen Arm; Neda Gholizadeh; Thibo Billiet; Rodney Lea; Jeannette Lechner-Scott; Saadallah Ramadan
Journal:  Neuroradiol J       Date:  2022-02-04

Review 8.  Why monkeys do not get multiple sclerosis (spontaneously): An evolutionary approach.

Authors:  Riley M Bove
Journal:  Evol Med Public Health       Date:  2018-01-23

Review 9.  Diagnosis and Management of Progressive Multiple Sclerosis.

Authors:  Gabrielle Macaron; Daniel Ontaneda
Journal:  Biomedicines       Date:  2019-07-29

10.  Multiparameter mapping of relaxation (R1, R2*), proton density and magnetization transfer saturation at 3 T: A multicenter dual-vendor reproducibility and repeatability study.

Authors:  Tobias Leutritz; Maryam Seif; Gunther Helms; Rebecca S Samson; Armin Curt; Patrick Freund; Nikolaus Weiskopf
Journal:  Hum Brain Mapp       Date:  2020-07-08       Impact factor: 5.399

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.